Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2013, Article ID 915381, 7 pages
http://dx.doi.org/10.1155/2013/915381
Research Article

Synthesis and Bioevaluation of Novel Imatinib Base Derivatives via 1,1′-Carbonyldiimidazole Catalyst

1Department of Chemistry, J.J.T. University, Rajasthan, India
2Department of Chemistry, Navjivan Science College, Gujarat University, Dahod, Gujarat 389151, India

Received 27 June 2013; Revised 19 September 2013; Accepted 21 September 2013

Academic Editor: Olga Gortzi

Copyright © 2013 M. J. Patoliya and G. J. Kharadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Li, J. Yang, X. Chen et al., “A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript,” Cancer Genetics and Cytogenetics, vol. 176, no. 2, pp. 166–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. I. El Hajj Dib, M. Gallet, R. Mentaverri, N. Sévenet, M. Brazier, and S. Kamel, “Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity,” European Journal of Pharmacology, vol. 551, no. 1–3, pp. 27–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. L. C. Crossman and S. O'Brien, “Clinical results with imatinib in chronic myeloid leukaemia,” Leukemia Research, vol. 28, no. 1, pp. S3–S9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. T. Van Oosterom, I. Judson, J. Verweij et al., “Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,” The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Buchdunger, C. L. Cioffi, N. Law et al., “Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 139–145, 2000. View at Google Scholar · View at Scopus
  6. G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger, “The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth,” Clinical Cancer Research, vol. 6, no. 8, pp. 3319–3326, 2000. View at Google Scholar · View at Scopus
  7. A. S. Ivanov and S. V. Shishkov, “Synthesis of imatinib: a convergent approach revisited,” Monatshefte fur Chemie, vol. 140, no. 6, pp. 619–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. Druker and N. B. Lydon, “Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia,” Journal of Clinical Investigation, vol. 105, no. 1, pp. 3–7, 2000. View at Google Scholar · View at Scopus
  9. B. J. Druker, S. Tamura, E. Buchdunger et al., “Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells,” Nature Medicine, vol. 2, no. 5, pp. 561–566, 1996. View at Google Scholar · View at Scopus
  10. B. J. Druker, M. Talpaz, D. J. Resta et al., “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” The New England Journal of Medicine, vol. 344, no. 14, pp. 1031–1037, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos et al., “Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment,” Blood, vol. 100, no. 3, pp. 1014–1018, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Hochhaus, S. Kreil, A. S. Corbin et al., “Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy,” Leukemia, vol. 16, no. 11, pp. 2190–2196, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Gorre, M. Mohammed, K. Ellwood et al., “Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification,” Science, vol. 293, no. 5531, pp. 876–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, and N. B. Lydon, “ABL-kinase: phenylaminopyridine (PAP) derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 7, pp. 187–192, 1997. View at Google Scholar
  15. H. Bredereck, F. Effenberger, and H. Bosch, “Säureamid-reaktionen, XLV. Untersuchungen über die reaktionsfähigkeit von formamidinen, dimethylformamid-diäthylacetal (Amidacetal) und Bis-dimethyl-amino-methoxy-methan (Aminalester),” Berichte der Deutschen Chemischen Gesellschaft, vol. 97, no. 12, pp. 3397–3406, 1964. View at Google Scholar
  16. A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, “Antibiotic susceptibility testing by a standardized single disk method,” The American Journal of Clinical Pathology, vol. 45, no. 4, pp. 493–496, 1966. View at Google Scholar · View at Scopus
  17. S. Satish, D. C. Mohana, M. P. Raghavendra, and K. A. Raveesha, “Antifungal activity of some plant extracts against important seed borne pathogens of Aspergillus sp.,” Journal of Agricultural Technology, vol. 3, pp. 109–119, 2007. View at Google Scholar